CAcTUS - Circulating Tumour DNA Guided Switch

PHASE2UnknownINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

April 26, 2023

Study Completion Date

May 2, 2024

Conditions
Melanoma
Interventions
OTHER

ctDNA analysis

Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.

Trial Locations (1)

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

University of Manchester

OTHER

collaborator

Manchester Academic Health Science Centre

OTHER

lead

The Christie NHS Foundation Trust

OTHER